Stromemycin is a C-glycosidic depside produced by a marine-derived Emericella sp. first isolated by Wink and coworkers at Aventis in 2001. Stromemycin inhibits stromelysin (metalloproteinase-3), an enzyme involved in the degradation of proteoglycans, constituents of cartilaginous tissue. Stromemycin has been patented for potential use for the treatment of connective tissue disorders. Due to lack of availability, the pharmacology of stromemycin has not been extensively investigated.